Alice Tseng
YOU?
Author Swipe
View article: International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During Coronavirus Disease 2019: Lessons Learned for Future Pandemic Preparedness
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During Coronavirus Disease 2019: Lessons Learned for Future Pandemic Preparedness Open
In December 2021 and January 2022, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antiviral drug, nirmatrelvir/ritonavir, was authorized in the United States, Canada, and Europe. However, ritonavir has significant drug-dr…
View article: “Weight and See”: Initial Weight Gain After Starting Antiretroviral Therapy Is Not Associated With Antiretroviral Regimen Type and Does Not Predict Subsequent Weight Trajectory
“Weight and See”: Initial Weight Gain After Starting Antiretroviral Therapy Is Not Associated With Antiretroviral Regimen Type and Does Not Predict Subsequent Weight Trajectory Open
In a Canadian cohort with HIV, 61% gained weight, 26% lost weight, and 12% remained stable in the first year of antiretroviral therapy. Weight gain was not associated with regimen type and slowed in years 2 to 3, with 44%, 34%, and 23% exp…
View article: Protocol of a drug–drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV
Protocol of a drug–drug interaction study between bictegravir/emtricitabine/tenofovir alafenamide and feminizing hormones in trans women living with HIV Open
Aims Trans/transfeminine women are disproportionally affected by HIV. Concerns regarding negative drug–drug interactions (DDIs) between ART drugs and gender‐affirming hormone therapy (GAHT), specifically feminizing hormone therapy (FHT), m…
View article: Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV
Aging on antiretrovirals: reviewing the need for pharmacologic data in elderly people with HIV Open
aWomen's Health Research Institute, British Columbia (BC) Women's Hospital, Vancouver bSimon Fraser University, Faculty of Health Sciences, Burnaby cOak Tree Clinic, BC Women's Hospital dFaculty of Pharmaceutical Sciences, UBC, Vancouver e…
View article: Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of <scp>HIV</scp>‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists
Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of <span>HIV</span>‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists Open
Five long‐acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV‐1 prevention or treatment—cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA AR…
View article: Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An executive summary
Consensus recommendations for use of long‐acting antiretroviral medications in the treatment and prevention of HIV‐1: Endorsed by the American Academy of HIV Medicine, American College of Clinical Pharmacy, Canadian HIV and Viral Hepatitis Pharmacists Network, European AIDS Clinical Society, and Society of Infectious Diseases Pharmacists: An executive summary Open
Five long‐acting (LA) antiretrovirals (ARVs) are currently available in a limited number of countries worldwide for HIV‐1 prevention or treatment – cabotegravir, rilpivirine, lenacapavir, ibalizumab, and dapivirine. Implementing use of LA …
View article: Moving forward to ‘put people first’
Moving forward to ‘put people first’ Open
In recent years, there has been recognition of the living/lived experiences and rights of trans and gender diverse people globally. In some countries, there have been legislative strides supporting the rights of trans and gender diverse pe…
View article: Oestradiol concentrations in trans women with HIV suppressed on unboosted integrase inhibitor regimens versus trans women without HIV taking oral oestradiol: a pilot study
Oestradiol concentrations in trans women with HIV suppressed on unboosted integrase inhibitor regimens versus trans women without HIV taking oral oestradiol: a pilot study Open
Background Feminizing hormone therapy (FHT) is essential to many trans women. Concern about negative drug interactions between FHT and ART can be an ART adherence barrier among trans women with HIV. Objectives In this single-centre, parall…
View article: A pharmacist-led interprofessional education program for family practice medical residents specializing in HIV care
A pharmacist-led interprofessional education program for family practice medical residents specializing in HIV care Open
Implication Statement We developed a pharmacist-led one-month teaching rotation for medical residents to learn HIV pharmacotherapy. This interprofessional education (IPE) was deemed extremely valuable by postgraduate-year-3 residents who i…
View article: Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV
Feminizing hormone therapy in a Canadian cohort of transgender women with and without HIV Open
Background Potential bidirectional drug–drug interactions between feminizing hormone therapy (FHT) and antiretroviral therapy (ART) are of concern for trans women with HIV and their healthcare providers. This study aimed to characterize pa…
View article: When beauty is more than skin deep
When beauty is more than skin deep Open
Para-phenylenediamine (PPD) is a widely used ingredient in hair dyes and black henna. Rarely, long-term use of topical PPD-containing products can lead to systemic absorption and toxicity, including chronic renal failure. We describe the f…
View article: Remdesivir in Patients With Severe Kidney Dysfunction
Remdesivir in Patients With Severe Kidney Dysfunction Open
This secondary analysis of a randomized clinical trial examines the risk of kidney or hepatic toxic effects among patients with impaired kidney function at baseline treated with remdesivir.
View article: A practical clinical guide to counselling on and managing contraception, pre-conception planning, and menopause for women living with HIV
A practical clinical guide to counselling on and managing contraception, pre-conception planning, and menopause for women living with HIV Open
Background: Women represent one quarter of the population living with HIV in Canada and are an increasingly important sector of the HIV community. While some women’s health issues such as cervical cancer screening and management are well a…
View article: COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations
COVID-19: A Review of Potential Treatments (Corticosteroids, Remdesivir, Tocilizumab, Bamlanivimab/Etesevimab, and Casirivimab/Imdevimab) and Pharmacological Considerations Open
Objectives: In light of the ongoing global pandemic, this paper reviews data on a number of potential and approved agents for COVID-19 disease management, including corticosteroids, remdesivir, tocilizumab, and monoclonal antibody combinat…
View article: P427 SUPPLeX: appearance and performance-enhancing supplements use in people on pre-exposure ProphyLaXis
P427 SUPPLeX: appearance and performance-enhancing supplements use in people on pre-exposure ProphyLaXis Open
Background Men-who-have-sex-with-men (MSM) may experience more body image dissatisfaction compared to heterosexual men. The desire to be muscular has been linked with use of appearance- and performance-enhancing supplements (APES), includi…
View article: 1470. Neurocognitively-Acting Potentially Inappropriate Medications, Alcohol, and Community-Acquired Pneumonia Among Patients with and Without HIV
1470. Neurocognitively-Acting Potentially Inappropriate Medications, Alcohol, and Community-Acquired Pneumonia Among Patients with and Without HIV Open
BACKGROUND: Alcohol interactions with neurocognitively-acting potentially inappropriate medications (NC-PIMs) may be more common, more harmful, and associated with lower levels of alcohol use among people living with HIV. METHODS: We condu…
View article: CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment
CIHR Canadian HIV Trials Network Coinfection and Concurrent Diseases Core Research Group: 2016 Updated Canadian HIV/Hepatitis C Adult Guidelines for Management and Treatment Open
Background . Hepatitis C virus (HCV) coinfection occurs in 20–30% of Canadians living with HIV and is responsible for a heavy burden of morbidity and mortality. Purpose . To update national standards for management of HCV-HIV coinfected ad…